Ruiz Puentes Paola, Henao Maria C, Cifuentes Javier, Muñoz-Camargo Carolina, Reyes Luis H, Cruz Juan C, Arbeláez Pablo
Center for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogota 111711, Colombia.
Department of Biomedical Engineering, Universidad de los Andes, Bogota 111711, Colombia.
Membranes (Basel). 2022 Jul 14;12(7):708. doi: 10.3390/membranes12070708.
Antibiotic resistance is a worldwide public health problem due to the costs and mortality rates it generates. However, the large pharmaceutical industries have stopped searching for new antibiotics because of their low profitability, given the rapid replacement rates imposed by the increasingly observed resistance acquired by microorganisms. Alternatively, antimicrobial peptides (AMPs) have emerged as potent molecules with a much lower rate of resistance generation. The discovery of these peptides is carried out through extensive in vitro screenings of either rational or non-rational libraries. These processes are tedious and expensive and generate only a few AMP candidates, most of which fail to show the required activity and physicochemical properties for practical applications. This work proposes implementing an artificial intelligence algorithm to reduce the required experimentation and increase the efficiency of high-activity AMP discovery. Our deep learning (DL) model, called AMPs-Net, outperforms the state-of-the-art method by 8.8% in average precision. Furthermore, it is highly accurate to predict the antibacterial and antiviral capacity of a large number of AMPs. Our search led to identifying two unreported antimicrobial motifs and two novel antimicrobial peptides related to them. Moreover, by coupling DL with molecular dynamics (MD) simulations, we were able to find a multifunctional peptide with promising therapeutic effects. Our work validates our previously proposed pipeline for a more efficient rational discovery of novel AMPs.
抗生素耐药性因其产生的成本和死亡率而成为一个全球性的公共卫生问题。然而,大型制药行业已经停止寻找新的抗生素,因为鉴于微生物获得的耐药性日益普遍,其替换速度很快,新抗生素的盈利能力较低。相比之下,抗菌肽(AMPs)已成为产生耐药性的比率低得多的有效分子。这些肽的发现是通过对合理或非合理文库进行广泛的体外筛选来实现的。这些过程既繁琐又昂贵,并且只能产生少数几个抗菌肽候选物,其中大多数未能显示出实际应用所需的活性和物理化学性质。这项工作提出实施一种人工智能算法,以减少所需的实验并提高高活性抗菌肽发现的效率。我们的深度学习(DL)模型AMPs-Net在平均精度方面比最先进的方法高出8.8%。此外,它在预测大量抗菌肽的抗菌和抗病毒能力方面非常准确。我们的搜索导致鉴定出两个未报道的抗菌基序以及与它们相关的两种新型抗菌肽。此外,通过将深度学习与分子动力学(MD)模拟相结合,我们能够找到一种具有有前景治疗效果的多功能肽。我们的工作验证了我们之前提出的用于更高效合理地发现新型抗菌肽的流程。